The Myeloproliferative Neoplasms Research Consortium (MPN-RC) is an inter-active group of laboratory scientists, clinical scientists, and a biostatistics team, who work in coordination to develop and evaluate treatments that will improve the survival of patients with myeloproliferative neoplasms (MPN). The overall goal of the MPN-RC is to merge the skills and efforts of its scientifically diverse membership to generate the scientific foundation for novel therapeutic strategies which will be evaluated in rigorous, well- constructed independent investigator-initiated clinical trials. The MPN-RC, formerly MPD-RC, opened its first trial over a decade ago. Investigators from over 30 institutions in the US, Canada, Europe, and Israel had treated over 300 patients diagnosed with myelofibrosis, polycythemia vera, thrombocythemia, and acute myeloid leukemia. Currently, the MPN-RC has investigators in 11 institutions around the US and in Canada.
